Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m2 iv) on Day 1, cisplatin (40 mg/m2 iv) on Days 1-3 and etoposide (100 mg/m2 iv) on Days 1-3 (or 80 mg/m2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|Publication status||Published - 1985|
ASJC Scopus subject areas
- Cancer Research